Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
October 31, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
October 29, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
October 23, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
October 16, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
October 11, 2024 08:30 ET
|
Perspective Therapeutics, Inc.
[212Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi)Prolonged progression-free survival and tumor response were observed in...
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
October 10, 2024 17:14 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
October 07, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
September 30, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
September 10, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
September 05, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...